Page 8 - Confidence Interval News Today

1. In this randomized controlled trial, the incidence of death was lower in heart failure patients who received cardiac-resynchronization therapy (CRT) versus those who received implantable cardioverter-defibrillators (ICD). 2. The time until death was longer in patients who received cardiac-resynchronization therapy than those who received implantable cardioverter-defibrillators. Evidence Rating Level: 1 (Excellent) Study Rundown: CRT

1. In two randomized, noninferiority trials, low-dose calcium in pregnant women with low dietary calcium intake was noninferior to high-dose supplementation in reducing the risk of pre-eclampsia. 2. Low-dose calcium was noninferior to high-dose calcium in reducing the risk of live preterm birth in the trial in India but not in Tanzania. Evidence Rating Level:

European banks want higher outlier thresholds to offset higher confidence level in new standard

1. In this randomized controlled trial, apixaban lowered the risk of stroke or systemic embolism significantly more than aspirin in patients with subclinical atrial fibrillation. 2. Apixaban was associated with a higher risk of major bleeding than aspirin. Evidence Rating Level: 1 (Excellent) Study Rundown: Symptomatic atrial fibrillation is a leading cause of stroke and stroke-related

It's arguably one of the most used weather statements both by meteorologists and the general public - "There's a __ % chance of rain/snow today". But what does

CheckMate -67T is the first Phase 3 trial of the subcutaneous formulation of Opdivo to evaluate and demonstrate noninferior pharmacokinetics, efficacy and safety vs. its intravenous...

Bristol Myers Squibb announced the first disclosure of data from the Phase 3 CheckMate -67T trial, evaluating the subcutaneous formulation of Opdivo co-formulated with Halozyme?s proprietary...

PRINCETON - Bristol Myers Squibb today announced that Opdivo plus Yervoy continued to demonstrate long-term survival results in the Phase 3 CheckMate -214 trial, reducing the risk of death by 28%...

1. In this randomized controlled trial, replacing biomass stoves with those using liquefied petroleum gas (LPG) during pregnancy did not reduce stunting in infants at one year despite reductions in household air pollution. 2. There was no appreciable difference in stunting in infants at six months between the biomass cookstove and liquefied petroleum gas cookstove

Opdivo in combination with CABOMETYX reduced the risk of death by 23% in the first-line treatment of advanced renal cell carcinoma vs. sunitinib Four-year results demonstrating continued benefits...